Phase I and pharmacokinetic study of OSI-211, a liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.

被引：0
|
作者：
Giles, F
Tallman, M
Garcia-Manero, G
Cortes, J
Thomas, D
Wierda, W
Verstovsek, S
Hamilton, M
Barrett, E
Albitar, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[3] OSI Pharmaceut Inc, Boulder, CO USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4732
引用
收藏
页码：251B / 251B
页数：1
相关论文
共 50 条
  • [1] Phase I study of OSI-211, a novel liposomal topoisomerase 1 (Topo 1) inhibitor, in patients with refractory leukemia
    Apostolidou, E
    Garcia-Manero, G
    Cortes, J
    Thomas, D
    Andreeff, M
    Keating, M
    Tallman, M
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 262B - 262B
  • [2] Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
    Giles, FJ
    Tallman, MS
    Garcia-Manero, G
    Cortes, JE
    Thomas, DA
    Wierda, WG
    Verstovsek, S
    Hamilton, M
    Barrett, E
    Albitar, M
    Kantarjian, HM
    CANCER, 2004, 100 (07) : 1449 - 1458
  • [3] A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer
    Seiden, MV
    Muggia, F
    Astrow, A
    Matulonis, U
    Campos, S
    Roche, M
    Sivret, J
    Rusk, J
    Barrett, E
    GYNECOLOGIC ONCOLOGY, 2004, 93 (01) : 229 - 232
  • [4] Phase I study to evaluate the safety, tolerability and pharmacokinetics of OSI-211 (Liposomal Lurtotecan) in combination with Carboplatin
    Twelves, C.
    Gokul, S.
    Jones, R. H.
    Boddy, A.
    Macham, M.
    Fishwick, K.
    Wheaton, J.
    Cameron, T.
    Calvert, A. H.
    ANNALS OF ONCOLOGY, 2004, 15 : 105 - 105
  • [5] Phase II study of OSI-211 (liposomal lurtotecan) in recurrent small-ceil lung cancer (SCLC)
    Ranson, M
    Dobbs, T
    Modiano, M
    Nicolson, M
    Fyfe, D
    Harper, P
    Sandler, A
    Cameron, T
    Ptaszynski, M
    LUNG CANCER, 2005, 49 : S327 - S327
  • [6] OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL
    Tomkinson, B
    Bendele, R
    Giles, FJ
    Brown, E
    Gray, A
    Hart, K
    LeRay, JD
    Meyer, D
    Pelanne, M
    Emerson, DL
    LEUKEMIA RESEARCH, 2003, 27 (11) : 1039 - 1050
  • [7] Randomized phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC).
    Poole, CJ
    Thomas, H
    Gore, M
    Dark, G
    Vasey, P
    Bailey, N
    Cameron, T
    van Duym, C
    Ptaszynski, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 459S - 459S
  • [8] Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck - An EORTC New Drug Development Group Study
    Duffaud, F
    Borner, M
    Chollet, P
    Vermorken, JB
    Bloch, J
    Degardin, M
    Rolland, F
    Dittrich, C
    Baron, B
    Lacombe, D
    Fumoleau, P
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (18) : 2748 - 2752
  • [9] Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies
    J.H.M. Schellens
    B. Heinrich
    M. Lehnert
    M.E. Gore
    S.B. Kaye
    P. Dombernowsky
    R. Paridaens
    A.T. van Oosterom
    J. Verweij
    W.J. Loos
    H. Calvert
    N. Pavlidis
    H. Cortes-Funes
    J. Wanders
    M. Roelvink
    C. Sessa
    K. Selinger
    P.S. Wissel
    T. Gamucci
    A.R. Hanauske
    Investigational New Drugs, 2002, 20 : 83 - 93
  • [10] Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies
    Schellens, JHM
    Heinrich, B
    Lehnert, M
    Gore, ME
    Kaye, SB
    Dombernowsky, P
    Paridaens, R
    van Oosterom, AT
    Verweij, J
    Loos, WJ
    Calvert, H
    Pavlidis, N
    Cortes-Funes, H
    Wanders, J
    Roelvink, M
    Sessa, C
    Selinger, K
    Wissel, PS
    Gamucci, T
    Hanauske, AR
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (01) : 83 - 93
12345